• Mashup Score: 0

    An exploratory LOOP study analysis hints that screening is more likely to help avert stroke if patients have elevated biomarkers.

    Tweet Tweets with this article
    • Using an implantable loop recorder #ILR to screen older individuals for #Afib may be more beneficial when #NTproBNP levels are high, according to a post hoc analysis of the #LOOP study @TCTMD @mmamas1973 @ShelleyZieroth @ShelleyWood2 https://t.co/0CvveUeTO8

  • Mashup Score: 13

    This parallel-design double-blind trial compares data for patients classified as NYHA class I, II, and III at randomization to assess variation in that classification over time and its association with both objective measures of heart failure severity and long-term prognosis.

    Tweet Tweets with this article
    • 🔥#PARADIGM_HF subanalysis Conferming what it’s known but should be scientifically proven 👉#NYHA c. dynamic change over time & is an incomplete predictor of outcome 🍀#NTproBNP stronger outcome predictor @gcfmd @mvaduganathan @gbiondizoccai @JJheart_doc https://t.co/CubKvxzVu5 https://t.co/K9GgIDcgg4

  • Mashup Score: 1

    AbstractBACKGROUND AND AIMS. Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalisation for heart failure and for death in patients with sym

    Tweet Tweets with this article
    • #Empagliflozin in #AMI: the #EMMY trial Empagliflozin initiated shortly after an AMI improves #NTproBNP, as well as structural and functional #EchoFirst parameters ( LVEF, E/e’, LVESV and LVEDV) without significant safety concerns https://t.co/hQ5jz3uOCH @escardio #HeartFailure https://t.co/BFsXhFZxT3

  • Mashup Score: 9

    This editorial refers to ‘Characteristics and natural history of early-stage cardiac transthyretin amyloidosis’, by S. Law et al., https://doi.org/10.1093/eurhe

    Tweet Tweets with this article
    • RT @ehj_ed: Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities... https://t.co/wp8uEMiFZJ #amyloidosis #HF…

    • Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities... https://t.co/wp8uEMiFZJ #amyloidosis #HF #cardiomyopathy #NTproBNP #cardiotwitter @escardio @ESC_Journals https://t.co/AyWow1S0W0